Role of host genetics in fibrosis

Fibrogenesis and Tissue Repair

Volumn 2, Issue 1, 2009, Pages

  Hold, Georgina L ^a   Untiveros, Paraskevi ^a   Saunders, Karin A ^a   El Omar, Emad M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955468078     PISSN: None     EISSN: 17551536     Source Type: Journal    
DOI: 10.1186/1755-1536-2-6     Document Type: Review

References (142)

1. Maher JJ, McGuire RF. Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J Clin Invest 1990, 86(5):1641-1648. 10.1172/JCI114886, 296914, 2243137.
2. Weiner FR, Giambrone MA, Czaja MJ, Shah A, Annoni G, Takahashi S, Eghbali M, Zern MA. Ito-cell gene expression and collagen regulation. Hepatolog 1990, 11(1):111-117.
3. Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 2007, 132(4):1311-1321. 10.1378/chest.06-2568, 17934117.
4. Higgins DF, Kimura K, Iwano M, Haase VH. Hypoxia-inducible factor signaling in the development of tissue fibrosis. Cell Cycle 2008, 7(9):1128-1132.
5. Kawaguchi Y, Suzuki K, Hara M, Hidaka T, Ishizuka T, Kawagoe M, Nakamura H. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 1994, 53(8):506-510. 10.1136/ard.53.8.506, 1005389, 7944634.
6. Abraham DJ, Vancheeswaran R, Dashwood MR, Rajkumar VS, Pantelides P, Xu SW, du Bois RM, Black CM. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997, 151(3):831-841. 1857854, 9284832.
7. Milani S, Herbst H, Schuppan D, Kim KY, Riecken EO, Stein H. Procollagen expression by nonparenchymal rat liver cells in experimental biliary fibrosis. Gastroenterology 1990, 98(1):175-184.
8. Maher JJ, Bissell DM, Friedman SL, Roll FJ. Collagen measured in primary cultures of normal rat hepatocytes derives from lipocytes within the monolayer. J Clin Invest 1988, 82(2):450-459. 10.1172/JCI113618, 303534, 3042806.
9. Parola M, Marra F, Pinzani M. Myofibroblast-like cells and liver fibrogenesis: Emerging concepts in a rapidly moving scenario. Mol Aspects Med 2008, 29(1-2):58-66. 10.1016/j.mam.2007.09.002, 18022682.
10. Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 2004, 126(2):529-540. 10.1053/j.gastro.2003.11.018, 14762790.
11. De Minicis S, Seki E, Uchinami H, Kluwe J, Zhang Y, Brenner DA, Schwabe RF. Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology 2007, 132(5):1937-1946. 10.1053/j.gastro.2007.02.033, 17484886.
12. Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C, Wilke CA, Toews GB. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol 2005, 166(3):675-684. 1780139, 15743780.
13. Kisseleva T, Uchinami H, Feirt N, Quintana-Bustamante O, Segovia JC, Schwabe RF, Brenner DA. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 2006, 45(3):429-438. 10.1016/j.jhep.2006.04.014, 16846660.
14. Gauldie J, Bonniaud P, Sime P, Ask K, Kolb M. TGF-beta, Smad3 and the process of progressive fibrosis. Biochem Soc Trans 2007, 35(Pt 4):661-664.
15. Leask A. Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. Cell Signal 2008, 20(8):1409-1414. 10.1016/j.cellsig.2008.01.006, 18296024.
16. Porter DW, Millecchia LL, Willard P, Robinson VA, Ramsey D, McLaurin J, Khan A, Brumbaugh K, Beighley CM, Teass A, Castranova V. Nitric oxide and reactive oxygen species production causes progressive damage in rats after cessation of silica inhalation. Toxicol Sci 2006, 90(1):188-197. 10.1093/toxsci/kfj075, 16339787.
17. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001, 35(2):297-306. 10.1016/S0168-8278(01)00142-8, 11580156.
18. Jaeschke H. Mechanisms of liver injury. II. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions. Am J Physiol - Gastrointestinal Liver Physiol 2006, 290(6):G1083-G1088.
19. Ruiz-Ortega M, Ruperez M, Esteban V, Egido J. Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep 2003, 5(1):73-79. 10.1007/s11906-003-0014-0, 12530939.
20. Cutroneo KRMS. TGF-beta-induced fibrosis and SMAD signaling: oligo decoys as natural therapeutics for inhibition of tissue fibrosis and scarring. Wound Repair Regeneration 2007, 15:S54-S60.
21. Inagaki Y, Okazaki I. Emerging insights into transforming growth factor β Smad signal in hepatic fibrogenesis. Gut 2007, 56(2):284-292. 10.1136/gut.2005.088690, 1856752, 17303605.
22. Verrecchia F, Mauviel A. TGF-β and TNF-α: antagonistic cytokines controlling type I collagen gene expression. Cell Signal 2004, 16(8):873-880. 10.1016/j.cellsig.2004.02.007, 15157666.
23. Ghosh AK. Factors involved in type I collagen gene expression: implication in scleroderma. Exp Biol Med 2002, 227:301-314.
24. Trojanowska M, Carwile LeRoy E, Eckes B, Krieg T. Pathogenesis of fibrosis: type 1 collagen and the skin. J Molec Med 1998, 76(3):266-274. 10.1007/s001090050216, 9535560.
25. Jimenez SA, Varga J, Olsen A, Li L, Diaz A, Herhal J, Koch J. Functional analog of human α1 (I) procollagen gene promoter: differential activity in collagen producing and nonproducing cells and response to transforming growth factor β1. J Biol Chem 1994, 269:12684-12691.
26. Chung KY, Agarwal A, Uitto J, Mauviel A. An AP-1 binding sequence is essential for regulation of the human alpha 2 (I) collagen (COL1A2) promoter activity by transforming growth factor-β. J Biol Chem 1996, 271:3272-3278. 10.1074/jbc.271.6.3272, 8621730.
27. Verrecchia F, Rossert J, Mauviel A. Blocking sp1 transcription factor broadly inhibits extracellular matrix gene expression in vitro and in vivo: implications for the treatment of tissue fibrosis. J Invest Dermatol 2001, 116(5):755-763. 10.1046/j.1523-1747.2001.01326.x, 11348466.
28. Chen SJ, Yuan W, Mori Y, Levenson A, Trojanowska M, Varga J. Stimulation of typeI collagen transcription in human skin fibroblasts by TGF-b: involvement of Smad 3. Invest Dermatol 1999, 112:49-57.
29. Poncelet AC, Schnaper HW. Sp1 and Smad proteins cooperate to mediate transforming growth factor-β1-induced α2 (I) collagen expression in human glomerular mesangial cells. J Biol Chem 2001, 276(10):6983-6992. 10.1074/jbc.M006442200, 11114293.
30. Greenwel P, Inagaki Y, Hu W, Walsh M, Ramirez F. Sp1 is required for the early response of alpha 2 (1) collagen to transforming growth factor-beta 1. J Biol Chem 1997, 272:19738-19745. 10.1074/jbc.272.32.19738, 9242631.
31. Shi Y, Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003, 113(6):685-700. 10.1016/S0092-8674(03)00432-X, 12809600.
32. Furukawa F, Matsuzaki K, Mori S, Tahashi Y, Yoshida K, Sugano Y, Yamagata H, Matsushita M, Seki T, Inagaki Y. p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology 2003, 38(4):879-889.
33. Yoshida K, Matsuzaki K, Mori S, Tahashi Y, Yamagata H, Furukawa F, Seki T, Nishizawa M, Fujisawa J, Okazaki K. Transforming growth factor-β and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. Am J Pathol 2005, 166(4):1029-1039. 1602385, 15793284.
34. Abecassis L, Rogier E, Vazquez A, Atfi A, Bourgeade MF. Evidence for a role of MSK1 in transforming growth factor-{beta}-mediated responses through p38 {alpha} and Smad signaling pathways. J Biol Chem 2004, 279(29):30474-30479. 10.1074/jbc.M403294200, 15133024.
35. Tsukada S, Westwick JK, Ikejima K, Sato N, Rippe RA. SMAD and p38 MAPK Signaling pathways independently regulate {alpha} 1 (I) collagen gene expression in unstimulated and transforming growth factor-{beta}-stimulated hepatic stellate cells. J Biol Chem 2005, 280(11):1055-1064.
36. Kretzschmar M, Doody J, Timokhina I, Massague J. A mechanism of repression of TGF-β/Smad signaling by oncogenic Ras. Genes Dev 1999, 13(7):804-816. 10.1101/gad.13.7.804, 316599, 10197981.
37. Reunanen N, Foschi M, Han J, Kahari VM. Activation of extracellular signal-regulated kinase 1/2 inhibits type I collagen expression by human skin fibroblasts. J Biol Chem 2000, 275(44):34634-34639. 10.1074/jbc.C000175200, 10926924.
38. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 2001, 194(6):809-821. 10.1084/jem.194.6.809, 2195954, 11560996.
39. Fichtner-Feigl S, Fuss IJ, Young CA, Watanabe T, Geissler EK, Schlitt HJ, Kitani A, Strober W. Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol 2007, 178(9):5859-5870.
40. Murata T, Taguchi J, Puri RK, Mohri H. Sharing of receptor subunits and signal transduction pathway between the IL-4 and IL-13 receptor system. Int J Hematol 1999, 69(1):13-20.
41. Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD. Interleukin-4 and interleukin-13 signaling connections maps. Science 2003, 300(5625):1527-1528. 10.1126/science.1085458, 12791978.
42. Joshi BH, Hogaboam C, Dover P, Husain SR, Puri RK. Role of interleukin-13 in cancer, pulmonary fibrosis and other T(H)2-type diseases. Vitam Horm 2006, 74:479-504. full_text, 17027527.
43. Lai EW, Joshi BH, Martiniova L, Dogra R, Fujisawa T, Leland P, de Krijger RR, Lubensky IA, Elkahloun AG, Morris JC, et al. Overexpression of interleukin 13 receptor {alpha}2 as a novel therapy for malignant pheochromocytoma. J Clin Endocrinol Metab 2009, 2730867, 19491224.
44. Jakubzick C, Choi ES, Carpenter KJ, Kunkel SL, Evanoff H, Martinez FJ, Flaherty KR, Toews GB, Colby TV, Travis WD, et al. Human pulmonary fibroblasts exhibit altered interleukin-4 and interleukin-13 receptor subunit expression in idiopathic interstitial pneumonia. Am J Pathol 2004, 164(6):1989-2001. 1615781, 15161635.
45. Jakubzick C, Kunkel SL, Joshi BH, Puri RK, Hogaboam CM. Interleukin-13 fusion cytotoxin arrests Schistosoma mansoni egg-induced pulmonary granuloma formation in mice. Am J Pathol 2002, 161(4):1283-1297. 1867284, 12368202.
46. Shimamura T, Fujisawa T, Husain SR, Kioi M, Nakajima A, Puri RK. Novel role of IL-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13R-directed cytotoxin in a rat model. J Immunol 2008, 181(7):4656-4665.
47. Kaviratne M, Hesse M, Leusink M, Cheever AW, Davies SJ, McKerrow JH, Wakefield LM, Letterio JJ, Wynn TA. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol 2004, 173(6):4020-4029.
48. Hemmann S, Graf J, Roderfeld M, Roeb E. Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 2007, 46(5):955-975. 10.1016/j.jhep.2007.02.003, 17383048.
49. Iredale JP, Benyon RC, Arthur MJ, Ferris WF, Alcolado R, Winwood PJ, Clark N, Murphy G. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology 1996, 24(1):176-184. 10.1002/hep.510240129, 8707259.
50. Knittel T, Mehde M, Kobold D, Saile B, Dinter C, Ramadori G. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1. J Hepatol 1999, 30(1):48-60. 10.1016/S0168-8278(99)80007-5, 9927150.
51. Lichtinghagen R, Bahr MJ, Wehmeier M, Michels D, Haberkorn CI, Arndt B, Flemming P, Manns MP, Boeker KHW. Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis. Clin Sci 2003, 105(3):373-382. 10.1042/CS20030098, 12760742.
52. Schuppan D, Ruehl M, Somasundaram R, Hahn EGMD. Matrix as a modulator of hepatic fibrogenesis. Sem Liver Disease 2001, 21(3):351-372.
53. Yata Y, Takahara T, Furui K, Zhang LP, Jin B, Watanabe A. Spatial distribution of tissue inhibitor of metalloproteinase-1 mRNA in chronic liver disease. J Hepatol 1999, 30(3):425-432. 10.1016/S0168-8278(99)80101-9, 10190725.
54. Yata Y, Takahara T, Furui K, Zhang LP, Watanabe A. Expression of matrix metalloproteinase-13 and tissue inhibitor of metalloproteinase-1 in acute liver injury. J Hepatol 1999, 30(3):419-424. 10.1016/S0168-8278(99)80100-7, 10190724.
55. Watanabe T, Niioka M, Hozawa S, Kameyama K, Hayashi T, Arai M, Ishikawa A, Maruyama K, Okazaki I. Gene expression of interstitial collagenase in both progressive and recovery phase of rat liver fibrosis induced by carbon tetrachloride. J Hepatol 2000, 33(2):224-235. 10.1016/S0168-8278(00)80363-3, 10952240.
56. Ikeda K, Wakahara T, Wang YQ, Kadoya H, Kawada N, Kaneda K. In vitro migratory potential of rat quiescent hepatic stellate cells and its augmentation by cell activation. Hepatology 1999, 29(6):1760-1767. 10.1002/hep.510290640, 10347119.
57. Zhou X, Hovell CJ, Pawley S, Hutchings MI, Arthur MJP, Iredale JP, Benyon RC. Expression of matrix metalloproteinase-2 and-14 persists during early resolution of experimental liver fibrosis and might contribute to fibrolysis. Liver Int 2004, 24(5):492-501. 10.1111/j.1478-3231.2004.0946.x, 15482348.
58. Takahara T, Furui K, Yata Y, Jin B, Zhang LP, Nambu S, Sato H, Seiki M, Watanabe A. Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers. Hepatology 1997, 26(6):1521-1529. 10.1002/hep.510260620, 9397993.
59. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. J Biol Chem 1995, 270(10):5331-5338. 10.1074/jbc.270.10.5331, 7890645.
60. Suzuki K, Enghild JJ, Morodomi T, Salvesen G, Nagase H. Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry (N Y) 1990, 29(44):10261-10270.
61. Nagase H, Enghild JJ, Suzuki K, Salvesen G. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl) mercuric acetate. Biochemistry (N Y) 1990, 29(24):5783-5789.
62. Imai K, Yokohama Y, Nakanishi I, Ohuchi E, Fujii Y, Nakai N, Okada Y. Matrix metalloproteinase 7 (MMP-7) from human rectal carcinoma cells: Activation of the precursor interaction with other matrix metalloproteinases and enzymic properties. Biol Chem 1995, 270:6691-6697.
63. Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G. Biochemical characterisation of human collagenase-3. J Biol Chem 1996, 271:1544-1550. 10.1074/jbc.271.3.1544, 8576151.
64. Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 1992, 267(6):3581-3584.
65. Knäuper V, Wilhelm SM, Seperack PK, DeClerck YA, Langley KE, Osthues A, Tschesche H. Direct activation of human neutrophil procollagenase by recombinant stromelysin. Biochem J 1993, 295(Pt 2):581-586. 1134920, 8240261.
66. Kossakowska AE, Edwards DR, Lee SS, Urbanski LS, Stabbler AL, Zhang CL, Phillips BW, Zhang Y, Urbanski SJ. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am J Pathol 1998, 153(6):1895-1902. 1866318, 9846979.
67. Jiang Y, Liu J, Waalkes M, Kang YJ. Changes in the gene expression associated with carbon tetrachloride-induced liver fibrosis persist after cessation of dosing in mice. Toxicol Sci 2004, 79:404-410. 10.1093/toxsci/kfh120, 15056808.
68. Murawaki Y, Ikuta Y, Okamoto K, Koda M, Kawasaki H. Serum matrix metalloproteinase-3(stromelysin-1) concentration in patients with chronic liver disease. J Hepatol 1999, 31(3):474-481. 10.1016/S0168-8278(99)80040-3, 10488707.
69. Takahara T, Furui K, Funaki J, Nakayama Y, Itoh H, Miyabayashi C, Sato H, Seiki M, Ooshima A, Watanabe A. Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats. Hepatology 1995, 21(3):787-795. 10.1002/hep.1840210328, 7875677.
70. Knittel T, Mehde M, Grundmann A, Saile B, Scharf JG, Ramadori G. Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat. Histochem Cell Biol 2000, 113(6):443-453.
71. Roderfeld M, Geier A, Dietrich CG, Siewert E, Jansen B, Gartung C, Roeb E. Cytokine blockade inhibits hepatic tissue inhibitor of metalloproteinase-1 expression and up-regulates matrix metalloproteinase-9 in toxic liver injury. Liver Int 2006, 26(5):579-586. 10.1111/j.1478-3231.2006.01271.x, 16762003.
72. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev 2000, 14(2):163-176. 316345, 10652271.
73. Cao Q, Mak K, Lieber CS. Dilinoleoylphosphatidylcholine (DLPC) decreases transforming growth factor-1-mediated collagen production by rat hepatic stellate cells. J Lab Clin Med 2002, 139:202-210. 10.1067/mlc.2002.121853, 12024107.
74. Bataller R, Brenner D. Liver fibrosis. J Clin Invest 2005, 115:209-218. 546435, 15690074.
75. Yoshiji H, Kuriyama S, Miyamoto Y, Thorgeirsson UP, Gomez DE, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 2000, 32(6):1248-1254. 10.1053/jhep.2000.20521, 11093731.
76. Murphy FR, Issa R, Zhou X, Ratnarajah S, Nagase H, Arthur MJP, Benyon C, Iredale JP. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition implications for reversibility of liver fibrosis. J Biol Chem 2002, 277(13):11069-11076. 10.1074/jbc.M111490200, 11796725.
77. Bahr MJ, el Menuawy M, Boeker KHW, Musholt PB, Manns MP, Lichtinghagen R. Cytokine gene polymorphisms and the susceptibility to liver cirrhosis in patients with chronic hepatitis C. Liver Int 2003, 23(6):420-425. 10.1111/j.1478-3231.2003.00873.x, 14986816.
78. Lichtinghagen R, Michels D, Haberkorn CI, Arndt B, Bahr M, Flemming P, Manns MP, Boeker KH. Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. J Hepatol 2001, 34(2):239-247. 10.1016/S0168-8278(00)00037-4, 11281552.
79. Roeb E, Rose-John S, Erren A, Edwards DR, Matern S, Graeve L, Heinrich PC. Tissue inhibitor of metalloproteinases-2 (TIMP-2) in rat liver cells is increased by lipopolysaccharide and prostaglandin E2. FEBS Lett 1995, 357(1):33-36. 10.1016/0014-5793(94)01301-G, 8001673.
80. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000, 405:847-856. 10.1038/35015718, 10866211.
81. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, Carter ND, Spector TD. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 1999, 8(1):93-97. 10.1093/hmg/8.1.93, 9887336.
82. Grainger DJ, Mosedale DE, Metcalfe JC. TGF-β in blood: a complex problem. Cytokine Growth Factor Rev 2000, 11(1-2):133-145. 10.1016/S1359-6101(99)00037-4, 10708961.
83. Wang H, Mengsteab S, Tag CG, Gao CF, Hellerbrand C, Lammert F, Gressner AM, Weiskirchen R. Transforming growth factor-beta1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol 2005, 11(13):1929-1936.
84. Gewaltig J, Mangasser-Stephan K, Gartung C, Biesterfeld S, Gressner AM. Association of polymorphisms of the transforming growth factor-β1 gene with the rate of progression of HCV-induced liver fibrosis. Clinica Chimica Acta 2002, 316(1-2):83-94.
85. Tag CG, Mengsteab S, Hellerbrand C, Lammert F, Gressner AM, Weiskirchen R. Analysis of the transforming growth factor-beta1 (TGF-beta1) codon 25 gene polymorphism by LightCycler-analysis in patients with chronic hepatitis C infection. Cytokine 2003, 24:173-181. 10.1016/j.cyto.2003.08.007, 14596813.
86. Österreicher CH, Datz C, Stickel F, Hellerbrand C, Penz M, Hofer H, Wrba F, Penner E, Schuppan D, Ferenci P. TGF-β1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis. Cytokine 2005, 31(2):142-148. 10.1016/j.cyto.2005.03.005, 15941661.
87. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, Purdie DM, Jonsson JR. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000, 31(4):828-833. 10.1053/he.2000.6253, 10733535.
88. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-[beta] 1 gene: association with transforming growth factor-[beta] 1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998, 66(8):1014-1020. 10.1097/00007890-199810270-00009, 9808485.
89. Yee LJ, Tang J, Herrera J, Kaslow RA, van Leeuwen DJ. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun 2000, 1(6):386-390. 10.1038/sj.gene.6363696, 11196686.
90. Kojima H, Hongo Y, Harada H, Inoue T, Miyaji K, Kashiwagi M, Momose T, Arisaka Y, Fukui H, Murai S. Long-term histological prognosis and serum fibrosis markers in chronic hepatitis C patients treated with interferon. J Gastroenterol Hepatol 2001, 16(9):1015-1021. 10.1046/j.1440-1746.2001.02569.x, 11595066.
91. Whyte M, Hubbard R, Melconi R, Whidborne M, Eaton V, Bingle C, Timms J, Duff G, Facchini A, Pacilli A. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-α gene polymorphisms. Am J Respiratory Crit Care Med 2000, 162(2):755-758.
92. Pantelidis P, Fanning G, Wells A, Welsh K, Du Bois R. Analysis of tumor necrosis factor-a, lymphotoxin-a, tumor necrosis factor receptor II and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001, 163:1432-1436.
93. Riha RL, Yang IA, Rabnott GC, Tunnicliffe AM, Fong KM, Zimmerman PV. Cytokine gene polymorphisms in idiopathic pulmonary fibrosis. Intern Med J 2004, 34(3):126-129. 10.1111/j.1444-0903.2004.00503.x, 15030461.
94. Eskdale J, Keijsers V, Huizinga T, Gallagher G. Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes Immun 1999, 1(2):151-155. 10.1038/sj.gene.6363656, 11196662.
95. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RGJ, Huizinga TWJ. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc National Acad Sci 1998, 95(16):9465-9470.
96. Tseng LH, Lin MT, Shau WY, Lin WC, Chang FY, Chien KL, Hansen J, Chen DS, Chen PJ. Correlation of interleukin-10 gene haplotype with hepatocellular carcinoma in Taiwan. Tissue Antigens 2006, 67(2):127-133. 10.1111/j.1399-0039.2006.00536.x, 16441483.
97. Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED, Hsing A, Huang WY, Hayes RB. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 2006, 66(8):4525-4530. 10.1158/0008-5472.CAN-05-3987, 16618781.
98. El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, Stanford JL, Mayne ST, Goedert J, Blot WJ, Fraumeni JF, Chow W. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003, 124(5):1193-1201. 10.1016/S0016-5085(03)00157-4, 12730860.
99. Wright M, Goldin R, Fabre A, Lloyd J, Thomas H, Trepo C, Pradat P, Thursz M. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 2003, 52(4):574-579. 10.1136/gut.52.4.574, 1773621, 12631672.
100. Knapp S, Hennig BJW, Frodsham AJ, Zhang L, Hellier S, Wright M, Goldin R, Hill AVS, Thomas HC, Thursz MR. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 2003, 55(6):362-369. 10.1007/s00251-003-0594-5, 12942209.
101. Hutyrova B, Pantelidis P, Drabek J, Zůrkova M, Kolek V, Lenhart K, Welsh KI, du Bois RM, Petrek M. Interleukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis. Am J Respiratory Crit Care Med 2002, 165(2):148-151.
102. Donaldson P, Agarwal K, Craggs A, Craig W, James O, Jones D. HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility. Gut 2001, 48(3):397-402. 10.1136/gut.48.3.397, 1760119, 11171832.
103. Dai CY, Chuang WL, Hsieh MY, Lee LP, Hou NJ, Chen SC, Lin ZY, Hsieh MY, Wang LY, Tsai JF. Polymorphism of interferon-gamma gene at position 874 and clinical characteristics of chronic hepatitis C. Translational Res 2006, 148(3):128-133.
104. Ben-Ari Z, Pappo O, Druzd T, Sulkes J, Klein T, Samra Z, Gadba R, Tambur AR, Tur-Kaspa R, Mor E. Role of cytokine gene polymorphism and hepatic transforming growth factor β1 expression in recurrent hepatitis C after liver transplantation. Cytokine 2004, 27(1):7-14. 10.1016/j.cyto.2004.03.009, 15207246.
105. Koziel M, Dudley D, Afdhal N, Grakoui A, Rice C, Choo Q, Houghton M, Walker B. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 1995, 96(5):2311. 10.1172/JCI118287, 185882, 7593618.
106. Lechmann M, Woitas RP, Langhans B, Kaiser R, Ihlenfeldt HG, Jung G, Sauerbruch T, Spengler U. Decreased frequency of HCV core-specific peripheral blood mononuclear cells with type 1 cytokine secretion in chronic hepatitis C. J Hepatol 1999, 31(6):971-978. 10.1016/S0168-8278(99)80307-9, 10604568.
107. Hellier S, Frodsham AJ, Hennig BJW, Klenerman P, Knapp S, Ramaley P, Satsangi J, Wright M, Zhang L, Thomas HC. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 2003, 38(6):1468-1476.
108. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86(3):367-378. 10.1016/S0092-8674(00)80110-5, 8756719.
109. Mühlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS, Herfarth H, Lock G, Schölmerich J, Hellerbrand C. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003, 125(4):1085-1093. 10.1016/S0016-5085(03)01213-7, 14517792.
110. Erhardt A, Maschner-Olberg A, Mellenthin C, Kappert G, Adams O, Donner A, Willers R, Niederau C, Haussinger D. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. J Hepatol 2003, 38(3):335-342. 10.1016/S0168-8278(02)00415-4, 12586300.
111. Geier A, Reugels M, Weiskirchen R, Wasmuth HE, Dietrich CG, Siewert E, Gartung C, Lorenzen J, Bosserhoff AK, Brugmann M. Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C. Liver Int 2004, 24(4):285-294. 10.1111/j.1478-3231.2004.0928.x, 15287851.
112. Reynolds WF, Patel K, Pianko S, Blatt LM, Nicholas JJ, McHutchison JG. A genotypic association implicates myeloperoxidase in the progression of hepatic fibrosis in chronic hepatitis C virus infection. Genes Immun 2002, 3(6):345-349. 10.1038/sj.gene.6363880, 12209361.
113. Hennig BJ, Hellier S, Frodsham AJ, Zhang L, Klenerman P, Knapp S, Wright M, Thomas HC, Thursz M, Hill AV. Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection. Genes Immun 2002, 3:359-367. 10.1038/sj.gene.6363883, 12209363.
114. Wozniak MA, Itzhaki RF, Faragher EB, James MW, Ryder SD, Irving WL. Apolipoprotein E-∋ 4 protects against severe liver disease caused by hepatitis C virus. Hepatology 2002, 36(2):456-463. 10.1053/jhep.2002.34745, 12143056.
115. Hsu LC, Park JM, Zhang K, Luo JL, Maeda S, Kaufman RJ, Eckmann L, Guiney DG, Karin M. The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature 2004, 428(6980):341-345. 10.1038/nature02405, 15029200.
116. Poltorak A, He X, Smirnova I, Liu MY, Huffel CV, Du X, Birdwell D, Alejos E, Silva M, Galanos C. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282(5396):2085-2088. 10.1126/science.282.5396.2085, 9851930.
117. Qureshi ST, Lariviere L, Leveque G, Clermont S, Moore KJ, Gros P, Malo D. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med 1999, 189(4):615-625. 10.1084/jem.189.4.615, 2192941, 9989976.
118. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005, 204(1):27-42. 10.1111/j.0105-2896.2005.00239.x, 15790348.
119. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003, 21:335-376. 10.1146/annurev.immunol.21.120601.141126, 12524386.
120. Janeway CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002, 20(1):197-216. 10.1146/annurev.immunol.20.083001.084359, 11861602.
121. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999, 11:115-122. 10.1016/S1074-7613(00)80086-2, 10435584.
122. Bowie AG, Haga IR. The role of Toll-like receptors in the host response to viruses. Mol Immunol 2005, 42(8):859-867. 10.1016/j.molimm.2004.11.007, 15829275.
123. Perry AK, Gang C, Zheng D, Hong T, Cheng G. The host type I interferon response to viral and bacterial infections. Cell Res 2005, 15(6):407-422. 10.1038/sj.cr.7290309, 15987599.
124. Akira S. TLR signaling. Curr Top Microbiol Immunol 2006, 311:1-16. full_text, 17048703.
125. Jiang Z, Georgel P, Du X, Shamel L, Sovath S, Mudd S, Huber M, Kalis C, Keck S, Galanos C. CD14 is required for MyD88-independent LPS signaling. Nat Immunol 2005, 6(6):565-570. 10.1038/ni1207, 15895089.
126. Meneghin A, Hogaboam CM. Infectious disease, the innate immune response, and fibrosis. J Clin Invest 2007, 117(3):530-538. 10.1172/JCI30595, 1804377, 17332880.
127. Kluwe J, Mencin A, Schwabe RF. Toll-like receptors, wound healing, and carcinogenesis. J Molec Med 2009, 87(2):125-138. 10.1007/s00109-008-0426-z, 2791674, 19089397.
128. Seki E, De Minicis S, Österreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat Med 2007, 13(11):1324-1332. 10.1038/nm1663, 17952090.
129. Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology 2006, 130(6):1886-1900. 10.1053/j.gastro.2006.01.038, 16697751.
130. Watanabe A, Hashmi A, Gomes DA, Town T, Badou A, Flavell RA, Mehal WZ. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 2007, 46(5):1509-1518. 10.1002/hep.21867, 17705260.
131. Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995, 108(1):218-224. 10.1016/0016-5085(95)90027-6, 7806045.
132. Nanji AA, French SW. Animal models of alcoholic liver disease--focus on the intragastric feeding model. Alcohol Res Health 2003, 27(4):325-330.
133. Enomoto N, Ikejima K, Yamashina S, Hirose M, Shimizu H, Kitamura T, Takei Y, Sato N, Thurman RG. Kupffer cell sensitization by alcohol involves increased permeability to gut-derived endotoxin. Alcoholism: Clinical Exp Res 2001, 25(6):51S-54S.
134. Aroor AR, Shukla SD. MAP kinase signaling in diverse effects of ethanol. Life Sci 2004, 74(19):2339-2364. 10.1016/j.lfs.2003.11.001, 15027449.
135. Isayama F, Hines IN, Kremer M, Milton RJ, Byrd CL, Perry AW, McKim SE, Parsons C, Rippe RA, Wheeler MD. LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice. Am J Physiol - Gastrointestinal Liver Physiol 2006, 290(6):1318-1328.
136. Kusumoto K, Uto H, Hayashi K, Takahama Y, Nakao H, Suruki R, Stuver SO, Ido A, Tsubouchi H. Interleukin-10 or tumor necrosis factor-α polymorphisms and the natural course of hepatitis C virus infection in a hyperendemic area of Japan. Cytokine 2006, 34(1-2):24-31. 10.1016/j.cyto.2006.03.011, 16698276.
137. Jen-Eing J, Jung-Fa T, Lee-Yea C, Mei-Shang H, Zu-Yau L, Min-Yuh H, Shin-Chern C, Wan-Lung C, Liang-Yen W, Ming-Lung Y. Tumor necrosis factor-α 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia (NY) 2007, 9(11):987-992.
138. Grove J, Daly AK, Bassendine MF, Gilvarry E, Day CP. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 2000, 46(4):540-545. 10.1136/gut.46.4.540, 1727883, 10716685.
139. Huang H, Shiffman ML, Cheung RC, Layden TJ, Friedman S, Abar OT, Yee L, Chokkalingam AP, Schrodi SJ, Chan J, et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 2006, 130(6):1679-1687. 10.1053/j.gastro.2006.02.032, 16697732.
140. Campos J, Gonzalez-Quintela A, Quinteiro C, Gude F, Perez LF, Torre JA, Vidal C. The -159C/T polymorphism in the promoter region of the CD14 gene is associated with advanced liver disease and higher serum levels of acute-phase proteins in heavy drinkers. Alcohol Clin Exp Res 2005, 29(7):1206-1213. 10.1097/01.ALC.0000171977.25531.7A, 16046876.
141. Huang H, Shiffman ML, Friedman S, Venkatesh R, Bzowej N, Abar OT, Rowland CM, Catanese JJ, Leong DU, Sninsky JJ. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology(Baltimore, Md.) 2007, 46(2):297-306.
142. Guo J, Loke J, Zheng F, Hong F, Yea S, Fukata M, Tarocchi M, Abar OT, Huang H, Sninsky JJ, Friedman SL. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology 2009, 49(3):960-968. 10.1002/hep.22697, 2891538, 19085953.